Abstract
Type 2 diabetes mellitus (T2DM) is a heterogeneous condition that is related to both defective insulin secretion and peripheral insulin resistance. Beta cells are the major organ for secreting insulin hence, it is important to maintain an adequate beta-cell mass in response to various changes. Insulin resistance is a major cause of T2DM leads to elevated free fatty acid (FFA) levels which increases beta-cell mass and insulin secretion to compensate for insulin insensitivity. Chronic increase of plasma FFA levels results in disturbances in lipid metabolism, which contributes to decreased beta-cell function and lipotoxicity thus promoting T2DM. In the present review, we have discussed the process of beta-cell destruction, the role of genes in contributing to the fast increase in the progression of T2DM in detail. More than 130 variants in various T2DM susceptibility and candidate genes have been discovered to be associated with T2DM. Still, these variants elucidate only a small amount of total heritability of T2DM. Further, there is also an inventory of presently used therapeutic tools and a review of novel therapeutic approaches like incretin-based therapies or sodium-glucose transporter-2 inhibitors. Additionally, providing a concise but comprehensive update, this review will be essential to every clinician involved in the treatment of diabetes mellitus.
Similar content being viewed by others
References
Oh YS, Bae GD, Baek DJ, Park EY, Jun HS. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol. 2018;9(07):1–10.
Prasad RB, Groop L. Genetics of type 2 diabetes—pitfalls and possibilities. Genes. 2015;6(1):87–123.
Armstrong D. Advanced protocols in oxidative stress III. Advanced Protocols in Oxidative Stress III. 2014;1208:1–477.
Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes : Indian scenario. 2007;(03):217–30.
Zatalia SR, Sanusi H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta medica Indonesiana. 2013;45(2):141–7.
Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6(3):456–80.
Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:587–91.
Hardie DG. AMP-activated protein kinase — an energy sensor that regulates all aspects of cell function. 2011;1895–908.
Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9):1681–8.
Abate N, Chandalia M, Satija P, Adams-huet B, Grundy SM, Sandeep S, et al. Susceptibility to type 2 diabetes. Diabetes. 2005;54(04):1207–13.
Lyssenko V, Laakso M. Genetic Screening for the Risk of Type 2 Diabetes: Worthless or valuable? Diabetes Care. 2013;36(Supplement_2):S120–6.
Jayashree S, Arindam M, Vijay K V. Genetic epidemiology of coronary artery disease : an Asian Indian perspective 2015;94(3):539–49.
Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress—a concise review. Saudi Pharmaceutical Journal. 2016;24(5):547–53.
Mccarthy M, Menzel S. The genetics of type 2 diabetes. 2010;195–9.
Berumen J, Orozco L, Betancourt-cravioto M, Gallardo H, Zulueta M, Mendizabal L, et al. Influence of obesity , parental history of diabetes and genes in type 2 diabetes : A case-control study. 2019;(1):1–15.
Meigs JB, Cupples LA, Wilson PWF. The Framingham Offspring Study. (23):2201–7.
Moran Y, Labrador L, Camargo ME, Fernández D, Chiurillo MA. type 2 diabetes in Venezuelans. 2016;
Wilding JPH, Bastien A., Norwood P, list JF, T’Joen C, Fiedorek FT. a study of Dapagliflozin in patients with type 2 diabetes receiving high doses of. Emerging Treatments and Technologies 2009;32(9):1656–62.
Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australasian Medical Journal. 2014;7(1):45–8.
McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in south Asians. Lancet. 1991;337(8):382–6.
Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. 2001;86(11):5366–71.
Introduction I. Monogenic Diabetes : What It Teaches Us on the Common Forms of Type 1 and Type 2 Diabetes. 2016;37(June):190–222.
Hevener AL, Olefsky JM, Reichart D, Nguyen MTA, Bandyopadyhay G, Leung HY, et al. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Investig. 2007;117(6):1658–69.
Wamique M, Ali W. Rizvi Fatima Nishat. Role of free fatty acid and elevated VLDL in type II diabetes mellitus - a review. EJPMR. 2015;2(7):115–9.
Iraj G. Clinical review 124: diabetic dyslipidemia : causes and consequences. J Clin Endocrinol Metab. 2001;86(3):965–71.
Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M, et al. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol. 2012;11:79.
Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol. 2013;4(03):1–12.
Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician. 2009;79(1):29–36.
Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine. 2012;4(4):251–68.
Saxena M, Agrawal CG, Srivastava N, Banerjee M. gene polymorphisms in type 2 diabetes. 2014;6(07):60–8.
Han SJ, Boyko EJ. The evidence for an obesity paradox in type 2 diabetes mellitus. Diabetes Metab J. 2018;42(3):179–87.
Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. Nat Rev Genet. 2009;10(12):872–8.
Avenue G. Heterogeneity in Healthy Women 2002;667–73.
Kayıkcıoglu M. Polymorphisms of lipid metabolism enzyme-coding genes in patients with diabetic dyslipidemia. The Anatolian Journal of Cardiology. 2017;6:313–21.
Khodaeian M, Enayati S, Tabatabaei-malazy O, Amoli MM. Association between genetic variants and diabetes mellitus in Iranian populations : a systematic review of observational studies. 2015.
Dasgupta S, Sirisha PVS, Neelaveni K, Anuradha K, Reddy BM. Association of CAPN10 SNPs and Haplotypes with Polycystic Ovary Syndrome among South Indian Women 2012;7(2):1–8.
McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010;141(2):210–7.
Mitchell KJ. What is complex about complex disorders? Genome Biol. 2012;13(1):1–11.
Spégel P, Bugliani M, Saxena R, Fex M, Pulizzi N. NIH Public Access. 2013;41(1):82–8.
Singh S. The genetics of type 2 diabetes mellitus : a review. JSR. 2011;55:35–48.
Wu Y, Ding Y, Tanaka Y, Zhang W. Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention. 2014;11.
Ganza ML, Wintfeld N, Li Q, Alas V, Langer J, Hammer M. The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States. Diabetol Metab Syndr. 2014;6(1):1–8.
Tanaka H, Yoshida S, Oshima H, Minoura H, Negoro K, Yamazaki T, et al. Chronic Treatment with Novel GPR40 Agonists Improve Whole- Body Glucose Metabolism Based on the Glucose-Dependent Insulin Secretion. 2013;40(09):443–52.
Solun B, Marcoviciu D, Dicker D. Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system. Curr Cardiol Rep 2013;15(8).
Feng ZC, Li J, Turco BA, Riopel M, Yee SP, Wang R. Critical role of c-kit in beta cell function: increased insulin secretion and protection against diabetes in a mouse model. Diabetologia. 2012;55(8):2214–25.
Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice and Research: Clinical Endocrinology and Metabolism [Internet]. 2009;23(4):479–86.
Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet. 2010;375(9):2196–8.
Trevisan R. The role of Vildagliptin in the therapy of type 2 diabetic patients with renal dysfunction. Diabetes Therapy. 2017;8(6):1215–26.
Wegrzyn P, Yarwood SJ, Fiegler N, Bzowska M, Koj A, Mizgalska D, et al. Mimitin - a novel cytokine-regulated mitochondrial protein. BMC Cell Biol. 2009;10:23.
Park YJ, Ao Z, Kieffer TJ, Chen H, Safikhan N, Thompson DM, et al. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia. 2013;56(3):508–19.
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999;91(2):151–6.
Zhang X, Zhang W, Saraf SL, Nouraie M, Han J, Gowhari M, et al. HHS Public Access. 2015;134(8):895–904.
Medicine S. Exercise and Type 2 Diabetes. 2010;33(12).
Raveendran AV, Deshpandae A, Joshi SR. Therapeutic role of yoga in type 2 diabetes. Endocrinol Metab. 2018;33(3):307–17.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest exists.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Himanshu, D., Ali, W. & Wamique, M. Type 2 diabetes mellitus: pathogenesis and genetic diagnosis. J Diabetes Metab Disord 19, 1959–1966 (2020). https://doi.org/10.1007/s40200-020-00641-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40200-020-00641-x